Repare Therapeutics Shifts Focus to Clinical Portfolio
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced a strategic shift to prioritize the development of its clinical-stage oncology programs. The company will concentrate on advancing its key programs—lunresertib, camonsertib, RP-1664, and RP-3467—while significantly reducing its preclinical…
Significant Need for Innovative Endovascular Devices to Treat BTA Disease in CLI Patients
Research by THE SAGE GROUP analyzes the prevalence, characteristics, comorbidities, and outcomes of below-the-ankle (BTA) disease, while also exploring the challenges of endovascular revascularization. BTA (below-the-ankle) disease involves atherosclerotic stenoses or occlusions in foot arteries, including the pedal artery, plantar…
SoundHound AI Partners with MUSC Health to Enhance Patient Access with AI
SoundHound AI, Inc. (Nasdaq: SOUN), a leader in voice artificial intelligence, announced that MUSC Health has launched an AI agent named Emily, powered by the Amelia Patient Engagement solution, to improve patient access and service. Emily, available 24/7, helps patients…
Delcath Systems Reports Positive Study Results on Liver Therapy for Uveal Melanoma
Delcath Systems, Inc. (Nasdaq: DCTH), a company specializing in interventional oncology for treating liver cancers, announced the publication of a clinical study in the journal Therapeutic Advances in Medical Oncology. The study, titled “Melanoma-specific survival of patients with uveal melanoma…
PatientPay and ClearGage Merge to Transform Healthcare Billing
PatientPay, a top provider of patient billing and payments for acute, ambulatory, and specialty care, and ClearGage, known for its healthcare estimate and payment solutions, have completed their merger. The combined entity will now operate as PatientPay, offering an advanced…
Fresenius Kabi Adds Generic Reproductive Health Option
Fresenius Kabi has introduced Cetrorelix Acetate for Injection, an FDA-approved, cost-effective generic option for women’s reproductive health. The kit, available immediately, includes one single-dose vial of 0.25 mg cetrorelix, a pre-filled syringe with 1 mL sterile water for injection, a…
UptimeHealth Announces Dental Fix Summit 2024 for Technicians
UptimeHealth, in partnership with the College of Biomedical Equipment Technology (CBET), is pleased to announce the Dental Fix Summit 2024. The event will be held from October 3-6, 2024, at the Embassy Suites by Hilton Nashville Airport. This four-day summit…
Pfizer Unveils PfizerForAll™ Digital Health Platform
Pfizer Inc. has launched PfizerForAll, a user-friendly digital platform designed to streamline healthcare access and management for Americans. The platform simplifies the process for individuals and families to take important health actions, such as seeking care, filling prescriptions, and finding…
Navigator Medicines Announces $100M for NAV-240 Autoimmune Therapy
Navigator Medicines, a biotech company focused on advancing biologics for immune regulation, announced a $100 million Series A financing and the in-licensing of NAV-240 and an OX40L-targeted portfolio from IMBiologics Corp. NAV-240, previously known as IMB101, is a clinical-stage bispecific…
McKesson to Acquire Majority Stake in Florida Cancer Specialists & Research Institute’s Core Ventures
McKesson Corporation (NYSE: MCK) has announced a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion in cash, representing about 70% ownership. Core Ventures, created by Florida Cancer Specialists…
Omnipod® 5 System FDA-Cleared for Type 2 Diabetes
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology with its Omnipod® brand, has announced that its Omnipod 5 Automated Insulin Delivery System is now FDA-cleared for adults with type 2 diabetes in the U.S. This makes Omnipod…
Gossamer Bio to Present Data at ERS Congress 2024
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has announced its participation in the European Respiratory Society (ERS) Congress…